KCNK12

Summary

KCNK12 (potassium two pore domain channel subfamily K member 12, HGNC:6274) is a protein-coding gene on chromosome 2p16.3, encoding Potassium channel subfamily K member 12 (Q9HB15). K(+) channel subunit that may homo- and heterodimerize to form functional channels with distinct regulatory and gating properties.

This gene encodes one of the members of the superfamily of potassium channel proteins containing two pore-forming P domains. The product of this gene has not been shown to be a functional channel, however, it may require other non-pore-forming proteins for activity.

Source: NCBI Gene 56660 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 72 total
• MANE Select transcript: NM_022055

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6274
Approved symbol	KCNK12
Name	potassium two pore domain channel subfamily K member 12
Location	2p16.3
Locus type	gene with protein product
Status	Approved
Aliases	THIK-2, THIK2, K2p12.1
Ensembl gene	ENSG00000184261
Ensembl biotype	protein_coding
OMIM	607366
Entrez	56660

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 1 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000327876, ENST00000493527

RefSeq mRNA: 1 — MANE Select: NM_022055 NM_022055

CCDS: CCDS1835

Canonical transcript exons

ENST00000327876 — 2 exons

Exon	Start	End
ENSE00001303467	47509290	47521808
ENSE00001890023	47569941	47570985

Expression profiles

Bgee: expression breadth ubiquitous, 106 present calls, max score 95.36.

FANTOM5 (CAGE): breadth broad, TPM avg 3.2512 / max 222.3933, expressed in 429 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
28232	3.2512	429

Top tissues by expression

247 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
olfactory bulb	UBERON:0002264	95.36	gold quality
trigeminal ganglion	UBERON:0001675	88.98	gold quality
dorsal root ganglion	UBERON:0000044	84.15	gold quality
inferior olivary complex	UBERON:0002127	82.23	silver quality
cerebellum	UBERON:0002037	79.23	gold quality
cerebellar cortex	UBERON:0002129	79.19	gold quality
cerebellar hemisphere	UBERON:0002245	79.17	gold quality
right hemisphere of cerebellum	UBERON:0014890	79.10	gold quality
sural nerve	UBERON:0015488	78.27	gold quality
primary visual cortex	UBERON:0002436	77.60	gold quality
entorhinal cortex	UBERON:0002728	77.55	silver quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	77.46	silver quality
tibial nerve	UBERON:0001323	76.91	gold quality
middle temporal gyrus	UBERON:0002771	76.58	silver quality
occipital lobe	UBERON:0002021	75.27	gold quality
Brodmann (1909) area 23	UBERON:0013554	74.42	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	74.06	gold quality
postcentral gyrus	UBERON:0002581	74.06	silver quality
parietal lobe	UBERON:0001872	73.55	silver quality
superior frontal gyrus	UBERON:0002661	72.42	gold quality
cortical plate	UBERON:0005343	71.84	gold quality
prefrontal cortex	UBERON:0000451	71.52	gold quality
endothelial cell	CL:0000115	71.11	gold quality
pons	UBERON:0000988	71.08	silver quality
frontal cortex	UBERON:0001870	70.99	gold quality
right frontal lobe	UBERON:0002810	70.72	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	70.67	gold quality
neocortex	UBERON:0001950	70.41	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	69.85	gold quality
spinal cord	UBERON:0002240	69.55	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-7008	yes	137.29
E-ANND-3	no	2.71
E-GEOD-99795	no	1.96

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

18 targeting KCNK12, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-4519	99.48	66.10	859
HSA-MIR-6761-5P	98.71	68.03	1504
HSA-MIR-1261	98.62	68.10	896
HSA-MIR-134-5P	97.11	66.52	976
HSA-MIR-3118	97.11	66.58	984
HSA-MIR-6857-3P	96.70	65.43	915
HSA-MIR-518B	93.85	64.62	111
HSA-MIR-518C-3P	93.85	64.62	111
HSA-MIR-518D-3P	93.85	64.59	111
HSA-MIR-518A-3P	93.85	64.90	108
HSA-MIR-518F-3P	93.85	64.93	108
HSA-MIR-526A-3P	93.85	65.32	108
HSA-MIR-4707-5P	90.95	65.69	110

Literature-anchored findings (GeneRIF, showing 4)

• THIK-1 and THIK-2 are abundantly expressed in the proximal and distal nephron of the mammalian kidney. (PMID:18209473)
• The cytoplasmic amino-terminal region of THIK2 (Nt-THIK2) contains an arginine-rich motif (RRSRRR) that acts as a retention/retrieval signal. (PMID:24163367)
• In cell and tissues co-expressing THIK1 and THIK2, heterodimeric channels may contribute to cell excitability. (PMID:25148687)
• Regulation of the two-pore domain potassium channel, THIK-1 and THIK-2, by G protein coupled receptors. (PMID:37099539)

Cross-species orthologs

16 orthologs

Organism	Symbol	Gene ID
danio_rerio	KCNK12	ENSDARG00000074530
mus_musculus	Kcnk12	ENSMUSG00000050138
rattus_norvegicus	Kcnk12	ENSRNOG00000016110
drosophila_melanogaster	Ork1	FBGN0017561
drosophila_melanogaster	Task7	FBGN0037690
drosophila_melanogaster	Task6	FBGN0038165
drosophila_melanogaster	CG10864	FBGN0038621
drosophila_melanogaster	CG42340	FBGN0259242
caenorhabditis_elegans		WBGENE00006661
caenorhabditis_elegans		WBGENE00006674
caenorhabditis_elegans		WBGENE00006675
caenorhabditis_elegans		WBGENE00006679
caenorhabditis_elegans		WBGENE00006685
caenorhabditis_elegans		WBGENE00006686
caenorhabditis_elegans		WBGENE00006695
caenorhabditis_elegans		WBGENE00006696

Paralogs (14): KCNK2 (ENSG00000082482), KCNK16 (ENSG00000095981), KCNK6 (ENSG00000099337), KCNK10 (ENSG00000100433), KCNK15 (ENSG00000124249), KCNK17 (ENSG00000124780), KCNK1 (ENSG00000135750), KCNK13 (ENSG00000152315), KCNK5 (ENSG00000164626), KCNK9 (ENSG00000169427), KCNK3 (ENSG00000171303), KCNK7 (ENSG00000173338), KCNK4 (ENSG00000182450), KCNK18 (ENSG00000186795)

Protein

Protein identifiers

Potassium channel subfamily K member 12 — Q9HB15 (reviewed: Q9HB15)

Alternative names: Tandem pore domain halothane-inhibited potassium channel 2

All UniProt accessions (1): Q9HB15

UniProt curated annotations — full annotation on UniProt →

Function. K(+) channel subunit that may homo- and heterodimerize to form functional channels with distinct regulatory and gating properties. Can heterodimerize with KCNK13 subunit to conduct K(+) outward rectifying currents at the plasma membrane. The homodimers are mainly retained in the endoplasmic reticulum compartment and may be targeted to the cell surface upon phosphorylation or other activation signals yet to be elucidated.

Subunit / interactions. Homodimer. Heterodimer with KCNK13.

Subcellular location. Cell membrane. Endoplasmic reticulum membrane.

Domain organisation. Each subunit contributes two pore-forming domains 1 and 2 which assemble to form a single pore with M2 and M4 transmembrane helices lining the central cavity and M1 and M3 facing the lipid bilayer. The transmembrane helices are bridged by the selectivity filters 1 and 2 that coordinate the permeant ions. Up to four ions can simultaneously occupy the selectivity filter and at least two elementary charges must translocate across the filter to convert it into the open conformation.

Similarity. Belongs to the two pore domain potassium channel (TC 1.A.1.8) family.

RefSeq proteins (1): NP_071338* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003280	2pore_dom_K_chnl	Family
IPR005410	2pore_dom_K_chnl_THIK	Family
IPR013099	K_chnl_dom	Domain

Pfam: PF07885

Catalyzed reactions (Rhea), 1 shown:

• K(+)(in) = K(+)(out) (RHEA:29463)

UniProt features (40 total): binding site 13, mutagenesis site 13, transmembrane region 4, topological domain 3, region of interest 3, intramembrane region 2, chain 1, glycosylation site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HB15-F1	73.40	0.40

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (13): 129; 129; 130; 130; 131; 131; 256; 256; 257; 257; 258; 258 …

Glycosylation sites (1): 78

Mutagenesis-validated functional residues (13):

Position	Phenotype
11	disrupts er retention/retrieval signal resulting in localization at the plasma membrane and k(+) channel conductance; wh
12	disrupts er retention/retrieval signal resulting in localization at the plasma membrane and k(+) channel conductance; wh
13	mimics the dephosphorylated state which decreases trafficking from the er to the plasma membrane.
13	mimics the phosphorylated state which increases trafficking from the er to the plasma membrane and leads to increased k(
14	disrupts er retention/retrieval signal resulting in localization at the plasma membrane and k(+) channel conductance; wh
15	disrupts er retention/retrieval signal resulting in localization at the plasma membrane and k(+) channel conductance; wh
16	disrupts er retention/retrieval signal resulting in localization at the plasma membrane and k(+) channel conductance; wh
131	acts as a dominant negative when it assembles with wild-type subunit, abolishing k(+) flux.
155	increases channel basal activity. results in 7-fold increase in current amplitude. displays additive gating effects and
158	increases channel basal activity. results in 6-fold increase in current amplitude. confers nonlinear i-v relationship, w
158	does not affect channel basal activity.
163	does not affect channel basal activity.
165	does not affect channel basal activity.

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-5576886	Phase 4 - resting membrane potential
R-HSA-397014	Muscle contraction
R-HSA-5576891	Cardiac conduction

MSigDB gene sets: 108 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_UP, GSE45365_NK_CELL_VS_CD11B_DC_UP, GOBP_POTASSIUM_ION_TRANSPORT, BENPORATH_ES_WITH_H3K27ME3, GGGTGGRR_PAX4_03, GCGCTTT_MIR518B_MIR518C_MIR518D, GOBP_MONOATOMIC_CATION_TRANSPORT, TGCTGAY_UNKNOWN, TCF11_01, TATA_C, AACTTT_UNKNOWN, HNF1_C, E12_Q6, TTTNNANAGCYR_UNKNOWN, IVANOVA_HEMATOPOIESIS_EARLY_PROGENITOR

GO Biological Process (4): potassium ion transmembrane transport (GO:0071805), monoatomic ion transport (GO:0006811), potassium ion transport (GO:0006813), monoatomic ion transmembrane transport (GO:0034220)

GO Molecular Function (7): potassium channel activity (GO:0005267), outward rectifier potassium channel activity (GO:0015271), potassium ion leak channel activity (GO:0022841), identical protein binding (GO:0042802), metal ion binding (GO:0046872), protein heterodimerization activity (GO:0046982), protein binding (GO:0005515)

GO Cellular Component (5): endoplasmic reticulum membrane (GO:0005789), plasma membrane (GO:0005886), monoatomic ion channel complex (GO:0034702), endoplasmic reticulum (GO:0005783), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Cardiac conduction	1
Muscle contraction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
potassium ion transport	1
monoatomic cation transmembrane transport	1
transport	1
metal ion transport	1
monoatomic ion transport	1
transmembrane transport	1
monoatomic cation channel activity	1
potassium ion transmembrane transporter activity	1
voltage-gated potassium channel activity	1
potassium channel activity	1
leak channel activity	1
protein binding	1
cation binding	1
protein dimerization activity	1
binding	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
membrane	1
cell periphery	1
transmembrane transporter complex	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

626 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KCNK12	KCNK13	Q9HB14	719
KCNK12	KCNK18	Q7Z418	705
KCNK12	KRT76	Q01546	666
KCNK12	KCNG3	Q8TAE7	472
KCNK12	STPG4	Q8N801	472
KCNK12	KCNK4	Q9NYG8	458
KCNK12	KCNN1	Q92952	446
KCNK12	KCNK7	Q9Y2U2	445
KCNK12	PRKACA	P17612	423
KCNK12	PRKACB	P22694	423
KCNK12	MSH2	P43246	422
KCNK12	NDRG4	Q9ULP0	414
KCNK12	PRKACG	P22612	413
KCNK12	GALNT17	Q6IS24	404
KCNK12	KCNMA1	Q12791	395

IntAct

5 interactions, top by confidence:

A	B	Type	Score
KCNK12	AXIN2	psi-mi:“MI:0915”(physical association)	0.370
KCNK13	KCNK12	psi-mi:“MI:2364”(proximity)	0.350
KCNK12	KCNK13	psi-mi:“MI:2364”(proximity)	0.350
KCNK12	KCNK12	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (2): KCNK12 (Two-hybrid), KCNK12 (Positive Genetic)

ESM2 similar proteins: A2AIR5, B1ATG9, O00459, O08908, O09009, O09010, O12971, O15303, O15399, O42224, O60391, O70141, O97583, P04629, P0C7J6, P23726, P35349, P52849, P52850, P56726, P97698, Q00961, Q01098, Q03391, Q0GA42, Q13467, Q13563, Q14957, Q2KJ92, Q2WF71, Q5NCH9, Q5QQ50, Q5ZIW1, Q62645, Q63788, Q6ZRP7, Q863I4, Q8NE01, Q8NES3, Q8TCU5

Diamond homologs: G3V8R8, G3V8V5, G5E845, O00180, O08581, O14649, O17185, O35111, O54912, O88454, O95069, O95279, P57789, P97438, Q0P5A0, Q23435, Q3LS21, Q3TBV4, Q5RD07, Q5UE96, Q5VSE6, Q63ZI0, Q6Q1P3, Q6VV64, Q7Z418, Q8BUW1, Q8R454, Q8R5I0, Q920B6, Q96T54, Q96T55, Q9ERS1, Q9ES08, Q9H427, Q9HB14, Q9HB15, Q9JIS4, Q9JL58, Q9NPC2, Q9NYG8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

72 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	33
Likely benign	29
Benign	5

Top pathogenic / likely-pathogenic (0)

SpliceAI

324 predictions. Top by Δscore:

Variant	Effect	Δscore
2:47521809:C:CC	acceptor_gain	0.9900
2:47521810:T:A	acceptor_loss	0.9900
2:47569935:GCTCA:G	donor_loss	0.9900
2:47569936:CTCA:C	donor_loss	0.9900
2:47569937:TCA:T	donor_loss	0.9900
2:47569938:CA:C	donor_loss	0.9900
2:47569939:ACCTA:A	donor_loss	0.9900
2:47569940:C:CG	donor_loss	0.9900
2:47569939:A:AC	donor_gain	0.9800
2:47569940:C:CC	donor_gain	0.9800
2:47565715:T:TA	donor_gain	0.9600
2:47569940:CCT:C	donor_gain	0.9500
2:47521806:AAC:A	acceptor_gain	0.9200
2:47521807:AC:A	acceptor_gain	0.9200
2:47521808:CC:C	acceptor_gain	0.9200
2:47529058:G:A	donor_gain	0.8900
2:47521804:GAAAC:G	acceptor_gain	0.8800
2:47540490:A:AC	donor_gain	0.8800
2:47540491:C:CC	donor_gain	0.8800
2:47521805:AAAC:A	acceptor_gain	0.8700
2:47569940:CCTA:C	donor_gain	0.8700
2:47521811:G:GC	acceptor_gain	0.8600
2:47569939:AC:A	donor_gain	0.8600
2:47569940:CC:C	donor_gain	0.8600
2:47563539:CTTG:C	acceptor_gain	0.8500
2:47563540:TTGT:T	acceptor_gain	0.8500
2:47537920:AG:A	donor_gain	0.8400
2:47565628:T:A	donor_gain	0.8300
2:47569940:CCTAT:C	donor_gain	0.8300
2:47520905:GTCTA:G	donor_loss	0.8000

AlphaMissense

2740 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:47521421:C:A	G260V	1.000
2:47521421:C:T	G260E	1.000
2:47521804:G:C	F132L	1.000
2:47521804:G:T	F132L	1.000
2:47521806:A:G	F132L	1.000
2:47569990:C:A	W114C	1.000
2:47569990:C:G	W114C	1.000
2:47521341:C:G	G287R	0.999
2:47521408:G:C	S264R	0.999
2:47521408:G:T	S264R	0.999
2:47521410:T:G	S264R	0.999
2:47521422:C:A	G260W	0.999
2:47521424:A:C	F259C	0.999
2:47521424:A:G	F259S	0.999
2:47521427:C:T	G258D	0.999
2:47521428:C:G	G258R	0.999
2:47521433:G:A	T256I	0.999
2:47521435:G:C	S255R	0.999
2:47521435:G:T	S255R	0.999
2:47521437:T:G	S255R	0.999
2:47521463:G:C	S246W	0.999
2:47521477:C:A	W241C	0.999
2:47521477:C:G	W241C	0.999
2:47521479:A:G	W241R	0.999
2:47521479:A:T	W241R	0.999
2:47521742:C:T	G153D	0.999
2:47521751:C:T	G150E	0.999
2:47521752:C:A	G150W	0.999
2:47521763:A:G	L146P	0.999
2:47521790:G:T	P137H	0.999

dbSNP variants (sampled 300 via entrez): RS1000006941 (2:47556865 G>A,C), RS1000013184 (2:47560331 C>T), RS1000079427 (2:47529126 A>G), RS1000081125 (2:47560716 A>C), RS1000099648 (2:47551602 C>G), RS1000131420 (2:47522368 T>C), RS1000179458 (2:47515955 T>A,C), RS1000248873 (2:47529115 C>G,T), RS1000258925 (2:47554396 G>A), RS1000263159 (2:47528868 C>G,T), RS1000299122 (2:47572111 C>T), RS1000338198 (2:47517202 G>A,T), RS1000400830 (2:47510196 C>T), RS1000427812 (2:47523228 G>A), RS1000450314 (2:47568842 G>A)

Disease associations

OMIM: gene MIM:607366 | disease phenotypes: MIM:120435

GenCC curated gene-disease

Mondo (2): Lynch syndrome 1 (MONDO:0007356), hereditary neoplastic syndrome (MONDO:0015356)

Orphanet (2): Lynch syndrome (Orphanet:144), Inherited cancer-predisposing syndrome (Orphanet:140162)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST000520_1	Vitiligo	7.000000e-06

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D009386	Neoplastic Syndromes, Hereditary	C04.700; C16.320.700
C537261	Lynch syndrome I (site-specific colonic cancer) (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: vgic — Two-pore domain potassium channels (K_2P)

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression, increases methylation	4
(+)-JQ1 compound	decreases expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Tunicamycin	increases expression	2
FR900359	increases phosphorylation	1
terbufos	increases methylation	1
butyraldehyde	increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
MT19c compound	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Arsenic Trioxide	increases expression	1
Amiodarone	increases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Carbamazepine	affects expression	1
Fonofos	increases methylation	1
Naled	affects expression	1
Parathion	increases methylation	1
Plant Extracts	decreases expression, affects cotreatment	1
Tretinoin	decreases expression	1
Aflatoxin B1	increases methylation	1
Thapsigargin	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_YA66	IDG-HEK293T-KCNK12-V5-OE	Transformed cell line	Female

Clinical trials (associated diseases)

29 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00001496	Not specified	COMPLETED	Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast Cancer
NCT00001898	Not specified	COMPLETED	Microarray Analysis for Human Genetic Disease
NCT00026884	Not specified	RECRUITING	Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
NCT02289326	Not specified	COMPLETED	Biomarker Monitoring in TP53 Mutation Carriers
NCT02958462	Not specified	RECRUITING	Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
NCT03160274	Not specified	RECRUITING	Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
NCT03426878	Not specified	COMPLETED	Cancer Health Assessments Reaching Many
NCT03857594	Not specified	ACTIVE_NOT_RECRUITING	Integrative Sequencing In Germline and Hereditary Tumours
NCT03973450	Not specified	UNKNOWN	Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia
NCT03979612	Not specified	UNKNOWN	Evaluation of the Adhesion to the GENEPY Network
NCT04261972	Not specified	ACTIVE_NOT_RECRUITING	Cell-free DNA in Hereditary And High-Risk Malignancies 1
NCT04494945	Not specified	RECRUITING	Identifying and Caring for Individuals With Inherited Cancer Syndrome
NCT04541654	Not specified	RECRUITING	Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
NCT04763915	Not specified	ACTIVE_NOT_RECRUITING	Improving Care After Inherited Cancer Testing
NCT05562778	Not specified	RECRUITING	Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
NCT05664867	Not specified	RECRUITING	Implementation of Population Cancer Genetic Services in Federally Qualified Health Centers (FQHC)
NCT05721326	Not specified	COMPLETED	Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition
NCT06096688	Not specified	RECRUITING	Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
NCT06654466	Not specified	RECRUITING	Closing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer
NCT06708429	Not specified	RECRUITING	Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
NCT06726642	Not specified	RECRUITING	CfDNA in Hereditary And High-risk Malignancies 2
NCT06914726	Not specified	ENROLLING_BY_INVITATION	Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes
NCT06927947	Not specified	RECRUITING	Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes
NCT06999954	Not specified	RECRUITING	Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform
NCT07052266	Not specified	RECRUITING	Trial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening
NCT07195071	Not specified	RECRUITING	Feasibility Trial of Combination of Obstetrical Carrier Screening and Hereditary Cancer Screening
NCT07378423	Not specified	RECRUITING	Questionnaire on Congenital Cancer Signs Through Self-Assessment
NCT07381985	Not specified	ENROLLING_BY_INVITATION	Strategy for Management of Patients With Hereditary Cancer Syndromes (HCS) in a Rural Environment
NCT07542405	Not specified	NOT_YET_RECRUITING	A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American Families